From: A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)
HLA-status
HLA-A*2402-matched
(n = 50)
HLA-A*2402-unmatched
(n = 46)
Response
CR
PR
SD
PD
Number
1
30
16
3
0
28
17
Response rate
31/50
(62.0%)
28/46
(60.9%)